{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:19:26Z","timestamp":1793319566477,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"research grants from the Ministry of Health, Labor, and Welfare of Japan","award":["(20FC1024"],"award-info":[{"award-number":["(20FC1024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00277-025-06318-w","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:58:19Z","timestamp":1742360299000},"page":"1507-1514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Challenges in managing iTTP: insights into ADAMTS13 inhibitor boosting during caplacizumab therapy"],"prefix":"10.1007","volume":"104","author":[{"given":"Haruyuki","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Shiwaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Bamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Nishikubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"issue":"10","key":"6318_CR1","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","volume":"130","author":"JE Sadler","year":"2017","unstructured":"Sadler JE (2017) Pathophysiology of thrombotic thrombocytopenic purpura. Blood 130(10):1181\u20131188. https:\/\/doi.org\/10.1182\/blood-2017-04-636431","journal-title":"Blood"},{"key":"6318_CR2","doi-asserted-by":"publisher","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","volume":"3","author":"JA Kremer Hovinga","year":"2017","unstructured":"Kremer Hovinga JA, Coppo P, Lammle B, Moake JL, Miyata T, Vanhoorelbeke K (2017) Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers 3:17020. https:\/\/doi.org\/10.1038\/nrdp.2017.20","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"6318_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJM199108083250604","volume":"325","author":"GA Rock","year":"1991","unstructured":"Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis study group. N Engl J Med 325(6):393\u2013397. https:\/\/doi.org\/10.1056\/NEJM199108083250604","journal-title":"N Engl J Med"},{"issue":"6","key":"6318_CR4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knobl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D, Investigators T (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374(6):511\u2013522. https:\/\/doi.org\/10.1056\/NEJMoa1505533","journal-title":"N Engl J Med"},{"issue":"4","key":"6318_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","volume":"380","author":"M Scully","year":"2019","unstructured":"Scully M, Cataland SR, Peyvandi F, Coppo P, Knobl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK, Investigators H (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380(4):335\u2013346. https:\/\/doi.org\/10.1056\/NEJMoa1806311","journal-title":"N Engl J Med"},{"issue":"8","key":"6318_CR6","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/bloodadvances.2020001834","volume":"5","author":"F Peyvandi","year":"2021","unstructured":"Peyvandi F, Cataland S, Scully M, Coppo P, Knoebl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F (2021) Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Adv 5(8):2137\u20132141. https:\/\/doi.org\/10.1182\/bloodadvances.2020001834","journal-title":"Blood Adv"},{"issue":"13","key":"6318_CR7","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1182\/blood.2020007599","volume":"137","author":"T Dutt","year":"2021","unstructured":"Dutt T, Shaw RJ, Stubbs M, Yong J, Bailiff B, Cranfield T, Crowley MP, Desborough M, Eyre TA, Gooding R, Grainger J, Hanley J, Haughton J, Hermans J, Hill Q, Humphrey L, Lowe G, Lyall H, Mohsin M, Nicolson PLR, Priddee N, Rampotas A, Rayment R, Rhodes S, Taylor A, Thomas W, Tomkins O, Van Veen JJ, Lane S, Toh CH, Scully M (2021) Real-world experience with Caplacizumab in the management of acute TTP. Blood 137(13):1731\u20131740. https:\/\/doi.org\/10.1182\/blood.2020007599","journal-title":"Blood"},{"issue":"6","key":"6318_CR8","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1182\/blood.2020008021","volume":"137","author":"P Coppo","year":"2021","unstructured":"Coppo P, Bubenheim M, Azoulay E, Galicier L, Malot S, Big\u00e9 N, Poullin P, Prov\u00f4t F, Martis N, Presne C, Moranne O, Benainous R, Dossier A, Seguin A, Hi\u00e9 M, Wynckel A, Delmas Y, Augusto JF, Perez P, Rieu V, Barbet C, Lhote F, Ulrich M, Rumpler AC, de Witte S, Krummel T, Veyradier A, Benhamou Y (2021) A regimen with Caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood 137(6):733\u2013742. https:\/\/doi.org\/10.1182\/blood.2020008021","journal-title":"Blood"},{"issue":"13","key":"6318_CR9","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1182\/bloodadvances.2020001987","volume":"4","author":"LA Volker","year":"2020","unstructured":"Volker LA, Kaufeld J, Miesbach W, Brahler S, Reinhardt M, Kuhne L, Muhlfeld A, Schreiber A, Gaedeke J, Tolle M, Jabs WJ, Ozcan F, Markau S, Girndt M, Bauer F, Westhoff TH, Felten H, Hausberg M, Brand M, Gerth J, Bieringer M, Bommer M, Zschiedrich S, Schneider J, Elitok S, Gawlik A, Gackler A, Kribben A, Schwenger V, Schoenermarck U, Roeder M, Radermacher J, Bramstedt J, Morgner A, Herbst R, Harth A, Potthoff SA, von Auer C, Wendt R, Christ H, Brinkkoetter PT, Menne J (2020) ADAMTS13 and VWF activities guide individualized Caplacizumab treatment in patients with aTTP. Blood Adv 4(13):3093\u20133101. https:\/\/doi.org\/10.1182\/bloodadvances.2020001987","journal-title":"Blood Adv"},{"issue":"6","key":"6318_CR10","doi-asserted-by":"publisher","first-page":"102185","DOI":"10.1016\/j.rpth.2023.102185","volume":"7","author":"P Agosti","year":"2023","unstructured":"Agosti P, De Leo P, Capecchi M, Ferrari B, Mancini I, Gattillo S, Trisolini SM, Rinaldi E, Podda GM, Prezioso L, Salutari P, Facchini L, Caramazza D, Tolomelli G, Artoni A, Peyvandi F (2023) Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry. Res Pract Thromb Haemost 7(6):102185. https:\/\/doi.org\/10.1016\/j.rpth.2023.102185","journal-title":"Res Pract Thromb Haemost"},{"issue":"14","key":"6318_CR11","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.2020009150","volume":"137","author":"A Cuker","year":"2021","unstructured":"Cuker A, Cataland SR, Coppo P, de la Rubia J, Friedman KD, George JN, Knoebl PN, Kremer Hovinga JA, Lammle B, Matsumoto M, Pavenski K, Peyvandi F, Sakai K, Sarode R, Thomas MR, Tomiyama Y, Veyradier A, Westwood JP, Scully M (2021) Redefining outcomes in immune TTP: an international working group consensus report. Blood 137(14):1855\u20131861. https:\/\/doi.org\/10.1182\/blood.2020009150","journal-title":"Blood"},{"issue":"18","key":"6318_CR12","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1182\/blood.2022018847","volume":"141","author":"N Prasannan","year":"2023","unstructured":"Prasannan N, Thomas M, Stubbs M, Westwood JP, de Groot R, Singh D, Scully M (2023) Delayed normalization of ADAMTS13 activity in acute thrombotic thrombocytopenic purpura in the Caplacizumab era. Blood 141(18):2206\u20132213. https:\/\/doi.org\/10.1182\/blood.2022018847","journal-title":"Blood"},{"issue":"9","key":"6318_CR13","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1182\/bloodadvances.2023012451","volume":"8","author":"K Saito","year":"2024","unstructured":"Saito K, Sakai K, Kubo M, Azumi H, Hamamura A, Ochi S, Amagase H, Kunieda H, Ogawa Y, Yagi H, Matsumoto M (2024) Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP. Blood Adv 8(9):2151\u20132159. https:\/\/doi.org\/10.1182\/bloodadvances.2023012451","journal-title":"Blood Adv"},{"issue":"10","key":"6318_CR14","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1111\/trf.13182","volume":"55","author":"A Isonishi","year":"2015","unstructured":"Isonishi A, Bennett CL, Plaimauer B, Scheiflinger F, Matsumoto M, Fujimura Y (2015) Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma. Transfusion 55(10):2321\u20132330. https:\/\/doi.org\/10.1111\/trf.13182","journal-title":"Transfusion"},{"issue":"4","key":"6318_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s12185-021-03197-5","volume":"114","author":"M Kayashima","year":"2021","unstructured":"Kayashima M, Sakai K, Harada K, Kanetake J, Kubo M, Hamada E, Hayakawa M, Hatakeyama K, Matsumoto M (2021) Strong association between insufficient plasma exchange and fatal outcomes in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura. Int J Hematol 114(4):415\u2013423. https:\/\/doi.org\/10.1007\/s12185-021-03197-5","journal-title":"Int J Hematol"},{"issue":"7","key":"6318_CR16","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","volume":"118","author":"M Scully","year":"2011","unstructured":"Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ (2011) A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 118(7):1746\u20131753. https:\/\/doi.org\/10.1182\/blood-2011-03-341131","journal-title":"Blood"},{"issue":"6","key":"6318_CR17","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1007\/s12185-020-02974-y","volume":"112","author":"M Kubo","year":"2020","unstructured":"Kubo M, Sakai K, Yoshii Y, Hayakawa M, Matsumoto M (2020) Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan. Int J Hematol 112(6):764\u2013772. https:\/\/doi.org\/10.1007\/s12185-020-02974-y","journal-title":"Int J Hematol"},{"issue":"9","key":"6318_CR18","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1182\/bloodadvances.2019031039","volume":"3","author":"L Sun","year":"2019","unstructured":"Sun L, Mack J, Li A, Ryu J, Upadhyay VA, Uhl L, Kaufman RM, Stowell CP, Dzik WS, Makar RS, Bendapudi PK (2019) Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. Blood Adv 3(9):1512\u20131518. https:\/\/doi.org\/10.1182\/bloodadvances.2019031039","journal-title":"Blood Adv"},{"issue":"3","key":"6318_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jtha.2022.11.010","volume":"21","author":"LA V\u00f6lker","year":"2023","unstructured":"V\u00f6lker LA, Kaufeld J, Balduin G, Merkel L, K\u00fchne L, Eichenauer DA, Osterholt T, H\u00e4gele H, Kann M, Grundmann F, Kolbrink B, Schulte K, G\u00e4ckler A, Kribben A, Boss K, Potthoff SA, Rump LC, Schmidt T, M\u00fchlfeld AS, Schulmann K, Hermann M, Gaedeke J, Sauerland K, Bramstedt J, Hinkel UP, Miesbach W, Bauer F, Westhoff TH, Bruck H, Buxhofer-Ausch V, M\u00fcller TJ, Wendt R, Harth A, Schreiber A, Seelow E, T\u00f6lle M, Gohlisch C, Bieringer M, Geuther G, Jabs WJ, Fischereder M, von Bergwelt-Baildon A, Sch\u00f6nermarck U, Knoebl P, Menne J, Brinkkoetter PT (2023) Impact of first-line use of Caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura. J Thromb Haemost 21(3):559\u2013572. https:\/\/doi.org\/10.1016\/j.jtha.2022.11.010","journal-title":"J Thromb Haemost"},{"key":"6318_CR20","doi-asserted-by":"publisher","unstructured":"Izquierdo CP, Mingot-Castellano ME, Fuentes AEK, Garc\u00eda-Arroba Peinado J, Cid J, Jimenez MM, Valcarcel D, G\u00f3mez-Segu\u00ed I, de la Rubia J, Martin P, Goterris R, Hern\u00e1ndez L, Tall\u00f3n I, Varea S, Fern\u00e1ndez M, Garc\u00eda-Mu\u00f1oz N, Vara M, Zarzoso MF, Garc\u00eda-Candel F, Paciello ML, Garc\u00eda-Garc\u00eda I, Zalba S, Campuzano V, Gala JM, Est\u00e9vez JV, Jim\u00e9nez GM, L\u00f3pez Lorenzo JL, Arias EG, Freir\u00eda C, Sol\u00e9 M, \u00c1vila Idrovo LF, Hern\u00e1ndez Castellet, Cruz JC, Lavilla N, P\u00e9rez-Monta\u00f1a E, Atucha A, Salinas JA, Del R, Rio-Garma J (2022) Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura. Blood Adv 6 (24):6219\u20136227. https:\/\/doi.org\/10.1182\/bloodadvances.2022008028","DOI":"10.1182\/bloodadvances.2022008028"},{"issue":"3","key":"6318_CR21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12185-022-03495-6","volume":"117","author":"Y Miyakawa","year":"2023","unstructured":"Miyakawa Y, Imada K, Ichikawa S, Uchiyama H, Ueda Y, Yonezawa A, Fujitani S, Ogawa Y, Matsushita T, Asakura H, Nishio K, Suzuki K, Hashimoto Y, Murakami H, Tahara S, Tanaka T, Matsumoto M (2023) The efficacy and safety of Caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2\/3 study. Int J Hematol 117(3):366\u2013377. https:\/\/doi.org\/10.1007\/s12185-022-03495-6","journal-title":"Int J Hematol"},{"issue":"2","key":"6318_CR22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.11739","volume":"93","author":"F Peyvandi","year":"2008","unstructured":"Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT, Fabris F, Zver S, R\u00e9ti M, Mikovic D, Karimi M, Giuffrida G, Laurenti L, Mannucci PM (2008) ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 93(2):232\u2013239. https:\/\/doi.org\/10.3324\/haematol.11739","journal-title":"Haematologica"},{"issue":"7","key":"6318_CR23","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1182\/blood-2006-02-006064","volume":"109","author":"S Ferrari","year":"2007","unstructured":"Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, Girma JP, Azoulay E, Brun-Buisson C, Fakhouri F, Mira JP, Oksenhendler E, Poullin P, Rondeau E, Schleinitz N, Schlemmer B, Teboul JL, Vanhille P, Vernant JP, Meyer D, Veyradier A (2007) Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 109(7):2815\u20132822. https:\/\/doi.org\/10.1182\/blood-2006-02-006064","journal-title":"Blood"},{"issue":"1","key":"6318_CR24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMc1905426","volume":"381","author":"DP Chander","year":"2019","unstructured":"Chander DP, Loch MM, Cataland SR, George JN (2019) Caplacizumab therapy without plasma exchange for acquired thrombotic thrombocytopenic purpura. N Engl J Med 381(1):92\u201394. https:\/\/doi.org\/10.1056\/NEJMc1905426","journal-title":"N Engl J Med"},{"issue":"4","key":"6318_CR25","doi-asserted-by":"publisher","first-page":"E76","DOI":"10.1002\/ajh.25715","volume":"95","author":"S Sukumar","year":"2020","unstructured":"Sukumar S, George JN, Cataland SR (2020) Shared decision making, thrombotic thrombocytopenic purpura, and Caplacizumab. Am J Hematol 95(4):E76\u2013e77. https:\/\/doi.org\/10.1002\/ajh.25715","journal-title":"Am J Hematol"},{"issue":"8","key":"6318_CR26","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1111\/trf.15823","volume":"60","author":"MS Irani","year":"2020","unstructured":"Irani MS, Sanchez F, Friedman K (2020) Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh-frozen plasma. Transfusion 60(8):1666\u20131668. https:\/\/doi.org\/10.1111\/trf.15823","journal-title":"Transfusion"},{"issue":"14","key":"6318_CR27","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1182\/blood.2023023780","volume":"144","author":"L K\u00fchne","year":"2024","unstructured":"K\u00fchne L, Kn\u00f6bl P, Eller K, Thaler J, Sperr WR, Gleixner K, Osterholt T, Kaufeld J, Menne J, Buxhofer-Ausch V, M\u00fchlfeld A, Seelow E, Schreiber A, Todorova P, Cukoski S, Jabs WJ, \u00d6zcan F, G\u00e4ckler A, Sch\u00f6nfelder K, Seibert FS, Westhoff T, Schwenger V, Eichenauer DA, V\u00f6lker LA, Brinkkoetter PT (2024) Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange. Blood 144(14):1486\u20131495. https:\/\/doi.org\/10.1182\/blood.2023023780","journal-title":"Blood"},{"key":"6318_CR28","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T (2014) IgG subclasses and allotypes: from structure to effector functions. Front Immunol 5:520. https:\/\/doi.org\/10.3389\/fimmu.2014.00520","journal-title":"Front Immunol"},{"issue":"5","key":"6318_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1744-9987.2011.00930.x","volume":"15","author":"N Hanafusa","year":"2011","unstructured":"Hanafusa N (2011) Theoretical basis of pathogenic substance removal during plasmapheresis. Ther Apher Dial 15(5):421\u2013430. https:\/\/doi.org\/10.1111\/j.1744-9987.2011.00930.x","journal-title":"Ther Apher Dial"},{"issue":"12","key":"6318_CR30","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1182\/bloodadvances.2022007025","volume":"6","author":"JS Shin","year":"2022","unstructured":"Shin JS, Subhan MO, Cambridge G, Guo Y, de Groot R, Scully M, Thomas M (2022) Alterations in B- and Circulating T-follicular helper cell subsets in immune thrombotic thrombocytopenic purpura. Blood Adv 6(12):3792\u20133802. https:\/\/doi.org\/10.1182\/bloodadvances.2022007025","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06318-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06318-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06318-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:11:11Z","timestamp":1745561471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06318-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6318"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06318-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K. S. received speaker fees from Sanofi and participated on the advisory boards for Takeda. Y. U. received speaker fees from Sanofi. M.M. provided consultancy services for Takeda, Alexion Pharma, and Sanofi; received speaker fees from Takeda, Alexion Pharma, Asahi Kasei Pharma, and Sanofi; and received research funding from Alexion Pharma, Chugai Pharmaceutical, Asahi Kasei Pharma, and Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}